表紙
市場調査レポート

前臨床画像 (体内) の世界市場予測 2019年:前臨床画像システム・前臨床画像試薬

Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging): Global Forecasts to 2019

発行 MarketsandMarkets 商品コード 256349
出版日 ページ情報 英文 187 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
前臨床画像 (体内) の世界市場予測 2019年:前臨床画像システム・前臨床画像試薬 Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging): Global Forecasts to 2019
出版日: 2015年01月30日 ページ情報: 英文 187 Pages
概要

世界の前臨床画像市場は、予測期間中に6.0%のCAGRで拡大すると予測されています。分子画像技術の進歩、合理的な創薬ツールとしての前臨床画像の受け入れ拡大、および前臨床研究におけるマルチモダリティ画像技術の需要増加が同市場の成長を促進しています。しかし、画像システムの高額な実行コストおよびライフサイエンス研究活動に対するNIH資金の削減は、市場を抑制する要因となっています。さらに、独立型前臨床画像モダリティの技術的な制限、および核画像システムにおける放射性同位体用途に関連した課題も、市場成長を抑制する一因となっています。

当レポートでは、世界の前臨床画像市場について調査し、モダリティ、試薬、および地域別の市場分析と予測を提供しており、競合環境の分析、および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 前臨床画像市場における魅力的な市場機会
  • 前臨床試薬市場:地域別
  • 前臨床画像システム:地域別
  • 前臨床画像システム市場:モダリティ別

第5章 市場概要

  • イントロダクション
  • 前臨床画像市場の区分
  • 前臨床画像市場の力学

第6章 産業考察

  • イントロダクション
  • バリューチェーン分析
  • サプライチェーン分析
  • 産業動向
  • ポーターのファイブフォース分析

第7章 世界の前臨床画像市場:モダリティ別

  • イントロダクション
  • 光画像システム
  • 前臨床核画像システム
  • マイクロMRI
  • マイクロ超音波
  • マイクロCT
  • 前臨床光音響画像システム
  • 前臨床磁性粒子画像(MPI)システム

第8章 世界の前臨床画像市場:試薬別

  • イントロダクション
  • 前臨床光学画像試薬
  • 前臨床核画像試薬
  • 前臨床MRI造影剤
  • 前臨床超音波造影剤
  • 前臨床CT造影剤

第9章 地域分析

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋州
  • その他の地域(ROW)

第10章 競合環境

  • 概要
  • 市場シェア分析:前臨床画像市場、主要企業別
  • 競合状況・動向

第11章 企業プロファイル

  • Perkinelmer, Inc.
    • 事業概要
    • 製品ポートフォリオ
    • 主要戦略
    • 主な発展動向
    • SWOT分析
  • Bruker Corporation
  • Fujifilm Visualsonics, Inc.
  • Mediso Ltd.
  • Trifoil Imaging
  • Mr Solutions Ltd.
  • Aspect Imaging
  • Biospace Lab S.A.
  • Li-Cor Biosciences
  • Milabs B.V.

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MD 3117

The global preclinical imaging market is estimated to grow at a CAGR of 6.0% from 2014 to 2019. Although mature markets (such as the U.S., Germany, France, and the U.K.) hold larger shares in the preclinical imaging market in 2014, the Asia-Pacific region is poised to grow at the highest CAGR of 8.2% in the next five years. Factors such as increased outsourcing of preclinical research activities to Asia-based CROs by big pharmaceutical and biotechnological companies, owing to low cost of research in these nations; and increased government funding for drug discovery and development activities in economically emerging counties are propelling the growth of the preclinical imaging market in Asia-Pacific region.

The growth of the global preclinical imaging market is driven by factors such as development of technologically advanced hybrid preclinical imaging systems such as PET/CT, PET/MRI, and PET/SPECT/CT; growing acceptance of preclinical imaging as a legitimate drug development tool; and rising volume of preclinical research. In addition, emerging markets offering lucrative growth and departure of major companies from preclinical imaging systems market are creating new growth opportunities for the preclinical imaging systems and reagents manufacturers. Nonetheless, declining NIH (National Institutes of Health) funding for life science research, high implementation cost of preclinical imaging devices, and high cost and data requirements for bringing new imaging technology are the key reasons hampering the growth of preclinical imaging market.

In this report, the preclinical imaging market has been segmented on the basis of modality (covering optical imaging, nuclear imaging, micro-MRI, micro-CT, micro-ultrasound, photoacoustic, and magnetic particle imaging systems), by type of reagents (including nuclear imaging reagents, optical imaging reagents, MRIcontrast agents, ultrasound contrast agents and CT contrast agents), and by region (North America, Europe, Asia Pacific, and Rest of the World). The optical imaging systems market is estimated to account for the largest share of the global preclinical imaging systems market in 2014. However, the nuclear imaging systems segment is expected to grow at the highest rate during the forecast period. Factors such as development of technologically advanced hybrid nuclear imaging systems such as PET/MRI and PET/SPECT/CT and rising adoption of these devices in the preclinical research are driving the grow of the preclinical nuclear imaging systems market.

Geographically, North America (comprising the U.S. and Canada) commands the largest share of 36.2% of the global preclinical imaging market in 2014, followed by Europe. The preclinical imaging market in North America is primarily driven by various factors high volume of preclinical research in this region, easy availability and accessibility of resources (such as radioactive tracers), and rising government funding for research and innovation in Canada.

However, declining funding budgets of the U.S. National Institutes of Health (NIH) for preclinical research studies and recent changes in the Canadian R&D tax credit program are negatively affecting the growth of preclinical imaging market in North America.

The global preclinical imaging market is highly fragmented and competitive with a large number of global and local manufacturers of preclinical imaging systems and reagents. As of 2013, the global preclinical imaging market was dominated by PerkinElmer, Inc. (U.S.) and Bruker Corporation (U.S.), which together accounted for ~45% share of the market. New product launches, partnerships, agreements, collaborations, and geographic expansions were the major strategies adopted by most of the market players to achieve growth in the preclinical imaging market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis -industry analysis (industry trends, and Porter's five force model), market share analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the preclinical imaging systems and reagents market, high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering a greater market share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on preclinical imaging products offered by the top 10 players in the preclinical imaging market. The report analyzes the preclinical imaging market by modality and type of reagent across four geographies
  • Product Development/Innovation: Detailed insights on current and upcoming technologies, research and development activities, and new product launches in the preclinical imaging market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various preclinical systems and reagents across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the preclinical systems and reagents market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the preclinical systems and reagents market

Table of Contents

1. Introduction

  • 1.1. Objectives of the Study
  • 1.2. Pre-Clinical Imaging Market Definition
  • 1.3. Pre-Clinical Imaging Market Scope
    • 1.3.1. Pre-Clinical Imaging Market Covered
    • 1.3.2. Years Considered for the Study
  • 1.4. Currency
  • 1.5. Limitations
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Research Data
    • 2.1.1. Secondary Data
      • 2.1.1.1. Key Data From Secondary Sources
    • 2.1.2. Primary Data
      • 2.1.2.1. Breakdown of Primaries
      • 2.1.2.2. Key Data From Primary Sources
      • 2.1.2.3. Key Industry Insights
  • 2.2. Pre-Clinical Imaging Market Size Estimation
    • 2.2.1.1. Bottom-Up Approach
    • 2.2.1.2. Top-Down Approach
  • 2.3. Breakdown and Data Triangulation
  • 2.4. Research Assumptions

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Current Scenario
  • 3.3. Future Outlook
  • 3.4. Conclusion

4. Premium Insights

  • 4.1. Attractive Market Opportunities in the Pre-Clinical Imaging Market
  • 4.2. Pre-Clinical Imaging Reagents Markets, By Region (2014)
  • 4.3. Pre-Clinical Imaging Systems, By Region (2014)
  • 4.4. Pre-Clinical Imaging Systems Market, By Modality, (2014-2019)

5. Market Overview

  • 5.1. Introduction
  • 5.2. Pre-Clinical Imaging Market Segmentation
    • 5.2.1. Pre-Clinical Imaging Market Segmentation, By Modality
    • 5.2.2. Pre-Clinical Imaging Market Segmentation, By Reagent
  • 5.3. Pre-Clinical Imaging Market Dynamics
    • 5.3.1. Drivers
      • 5.3.1.1. Advancements in Molecular Imaging Technologies
      • 5.3.1.2. Growing Acceptance of Pre-Clinical Imaging as A Legitimate Drug Development Tool
      • 5.3.1.3. Increasing Demand for Multi-Modality Imaging Technologies in Pre-Clinical Research
      • 5.3.1.4. Increasing Number of Pre-Clinical Research Activities
    • 5.3.2. Restraints
      • 5.3.2.1. High Implementation Costs of Imaging Systems
      • 5.3.2.2. Reduced Nih Funding for Life Science Research Activities
      • 5.3.2.3. High Cost and Data Requirements for Developing New Imaging Technologies
    • 5.3.3. Opportunities
      • 5.3.3.1. Emerging Markets Offer Lucrative Growth Opportunities for Pre-Clinical Imaging Market Players
      • 5.3.3.2. Major Companies Exiting From the Pre-Clinical Imaging Market is Opening New Growth Avenues for Existing Market Players
      • 5.3.3.3. Integration of Preclinical MRI Systems With Other Imaging Modalities
      • 5.3.3.4. Development of Low-Cost Imaging Devices With High Resolution and Sensitivity
    • 5.3.4. Challenges
      • 5.3.4.1. Technological Limitations of Standalone Pre-Clinical Imaging Modalities
      • 5.3.4.2. Challenges Associated With the Application of Radioisotopes Negatively Affects the Demand of Micro-PET Systems

6. Industry Insights

  • 6.1. Introduction
  • 6.2. Value Chain Analysis
  • 6.3. Supply Chain Analysis
    • 6.3.1. Key Stakeholders
    • 6.3.2. Key Influencers
  • 6.4. Industry Trends
    • 6.4.1. Rising Focus of Market Players Towards the Development of Hybrid Pre-Clinical Imaging Systems
    • 6.4.2. Increasing Government Funding for Pharmaceutical Research and Development in Emerging Nations
  • 6.5. Porter's Five Forces Analysis
    • 6.5.1. Threat From New Entrants
    • 6.5.2. Threat From Substitutes
    • 6.5.3. Bargaining Power of Suppliers
    • 6.5.4. Bargaining Power of Buyers
    • 6.5.5. Intensity of Competitive Rivalry

7. Global Pre-Clinical Imaging Market, By Modality

  • 7.2. Introduction
  • 7.3. Optical Imaging Systems
    • 7.3.1. Bioluminescence/Fluorescence Imaging Systems
    • 7.3.2. Standalone Fluorescence Imaging Systems
    • 7.3.3. Optical + X-Ray/Optical + CT
  • 7.4. Pre-Clinical Nuclear Imaging Systems
    • 7.4.1. Micro-PET Systems
      • 7.4.1.1. Standalone PET Systems
      • 7.4.1.2. PET/CT Systems
      • 7.4.1.3. PET/MRI Systems
    • 7.4.2. Micro-SPECT Systems
      • 7.4.2.1. Standalone SPECT Systems
      • 7.4.2.2. SPECT/CT Systems
      • 7.4.2.3. SPECT/MRI Systems
    • 7.4.3. Trimodality (SPECT/PET/CT) Systems
  • 7.5. Micro-MRI
  • 7.6. Micro-Ultrasound
  • 7.7. Micro-CT
  • 7.8. Pre-Clinical Photoacoustic Imaging Systems
  • 7.9. Pre-Clinical Magnetic Particle Imaging (MPI) Systems

8. Global Pre-Clinical Imaging Market, By Reagents

  • 8.1. Introduction
  • 8.2. Pre-Clinical Optical Imaging Reagents
    • 8.2.1. Bioluminescent Imaging Reagents
      • 8.2.1.1. Luciferins
      • 8.2.1.2. Proluciferins
      • 8.2.1.3. Coelenterazine
      • 8.2.1.4. Others
    • 8.2.2. Fluorescent Imaging Reagents
      • 8.2.2.1. Green Fluorescent Proteins
      • 8.2.2.2. Red Fluorescent Proteins
      • 8.2.2.3. Infrared Dyes
      • 8.2.2.4. Others (Natural Fluorescence Molecules Such as Collagen and Elastin)
  • 8.3. Pre-Clinical Nuclear Imaging Reagents
    • 8.3.1. Pre-Clinical PET Tracers
      • 8.3.1.1. Fluorine-18-Based Preclinical PET Tracers
      • 8.3.1.2. Carbon-11-Based Preclinical PET Tracers
      • 8.3.1.3. Copper-64-Based Preclinical PET Tracers
      • 8.3.1.4. Others
    • 8.3.2. Pre-Clinical SPECT Probes
      • 8.3.2.1. Technetium-99m-Based Preclinical SPECT Probes
      • 8.3.2.2. Iodine-131-Based Preclinical SPECT Probes
      • 8.3.2.3. Gallium-67-Based Preclinical SPECT Probes
      • 8.3.2.4. Thallium-201-Based Preclinical SPECT Probes
      • 8.3.2.5. Others
  • 8.4. Pre-Clinical MRI Contrast Agents
    • 8.4.1. Gadolinium-Based Pre-Clinical MRI Contrast Agents
    • 8.4.2. Iron-Based Pre-Clinical MRI Contrast Agents
    • 8.4.3. Manganese-Based Pre-Clinical MRI Contrast Agents
  • 8.5. Pre-Clinical Ultrasound Contrast Agents
  • 8.6. Pre-Clinical CT Contrast Agents
    • 8.6.1. Iodine-Based Pre-Clinical CT Contrast Agents
    • 8.6.2. Barium-Based Pre-Clinical CT Contrast Agents
    • 8.6.3. Gold Nanoparticles
    • 8.6.4. Gastrografin-Based Pre-Clinical CT Contrast Agents

9. Geographic Analysis

  • 9.1. Introduction
  • 9.2. North America
  • 9.3. Europe
  • 9.4. Asia-Pacific
  • 9.5. Rest of the World (RoW)

10. Competitive Landscape

  • 10.1. Overview
  • 10.2. Market Share Analysis: Pre-Clinical Imaging Market, By Key Player, 2013
  • 10.3. Competitive Situation and Trends
    • 10.3.1. New Product Launches and Product Developments
    • 10.3.2. Agreements, Partnerships, and Collaborations
    • 10.3.3. Geographical Expansions
    • 10.3.4. Mergers and Acquisitions
    • 10.3.5. Other Developments

11. Company Profiles

  • 11.1. Perkinelmer, Inc.
    • 11.1.1. Business Overview
    • 11.1.2. Product Portfolio
    • 11.1.3. Key Strategy
    • 11.1.4. Key Developments (2012-2014)
    • 11.1.5. SWOT Analysis
  • 11.2. Bruker Corporation
    • 11.2.1. Business Overview
    • 11.2.2. Product Portfolio
    • 11.2.3. Key Strategy
    • 11.2.4. Key Developments (2012-2014)
    • 11.2.5. SWOT Analysis
  • 11.3. Fujifilm Visualsonics, Inc.
    • 11.3.1. Business Overview
    • 11.3.2. Product Portfolio
    • 11.3.3. Key Strategy
    • 11.3.4. Key Developments (2012-2014)
    • 11.3.5. SWOT Analysis
  • 11.4. Mediso Ltd.
    • 11.4.1. Business Overview
    • 11.4.2. Product Portfolio
    • 11.4.3. Key Strategy
    • 11.4.4. Key Developments (2012-2014)
    • 11.4.5. SWOT Analysis
  • 11.5. Trifoil Imaging
    • 11.5.1. Business Overview
    • 11.5.2. Product Portfolio
    • 11.5.3. Key Strategy
    • 11.5.4. Key Developments (2012-2014)
  • 11.6. Mr Solutions Ltd.
    • 11.6.1. Business Overview
    • 11.6.2. Product Portfolio
    • 11.6.3. Key Strategy
    • 11.6.4. Key Developments (2012-2014)
  • 11.7. Aspect Imaging
    • 11.7.1. Business Overview
    • 11.7.2. Product Portfolio
    • 11.7.3. Key Strategy
    • 11.7.4. Key Developments (2012-2014)
  • 11.8. Biospace Lab S.A.
    • 11.8.1. Business Overview
    • 11.8.2. Product Portfolio
    • 11.8.3. Key Strategy
    • 11.8.4. Key Developments (2012-2014)
  • 11.9. Li-Cor Biosciences
    • 11.9.1. Business Overview
    • 11.9.2. Product Portfolio
    • 11.9.3. Key Strategy
    • 11.9.4. Key Developments (2012-2014)
  • 11.1. Milabs B.V.
    • 11.10.1. Business Overview
    • 11.10.2. Product Portfolio
    • 11.10.3. Key Strategy
    • 11.10.4. Key Developments (2012-2014)

12. Appendix

  • 12.1. Insights of Industry Experts
  • 12.2. Discussion Guide*
  • 12.3. Company Developments (2012-2014)
    • 12.3.1. Aspect Imaging
    • 12.3.2. Bruker Corporation
    • 12.3.3. Li-Cor Biosciences
    • 12.3.4. Mediso Ltd.
    • 12.3.5. Milabs B.V.
    • 12.3.6. Perkinelmer, Inc.
  • 12.4. Introducing RT: Real-Time Market Intelligence
  • 12.5. Available Customizations
  • 12.6. Related Reports

List of Tables

  • Table 1: Pre-Clinical Imaging Systems Market Size, By Modality, 2012-2019 ($Million)
  • Table 2: Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 3: Global Optical Imaging Systems Market Size, By Type, 2012-2019 ($Million)
  • Table 4: Optical Imaging Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 5: Bioluminescence/Fluorescence Imaging Systems Market Size, By Region, 2012-2014 ($Million)
  • Table 6: Standalone Fluorescence Imaging Systems Market Size, By Region, 2012-2014 ($Million)
  • Table 7: Optical + X-Ray/Optical + CT Imaging Systems Market Size, By Region, 2012-2014 ($Million)
  • Table 8: Global Pre-Clinical Nuclear Imaging Systems Market Size, By Type, 2012-2019 ($Million)
  • Table 9: Pre-Clinical Nuclear Imaging Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 10: Global Micro-PET Systems Market Size, By Type, 2012-2019 ($Million)
  • Table 11: Micro-PET Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 12: Standalone PET Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 13: PET/CT Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 14: PET/MRI Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 15: Global Micro-SPECT Systems Market Size, By Type, 2012-2019 ($Million)
  • Table 16: Micro-SPECT Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 17: Standalone SPECT Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 18: SPECT/CT Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 19: Micro-MRI Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 20: Micro-Ultrasound Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 21: Micro-CT Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 22: Pre-Clinical Photoacoustic Imaging Systems Market Size, By Region, 2012-2019 ($Million)
  • Table 23: Global Pre-Clinical Imaging Reagents Market Size, By Type, 2012-2019 ($Million)
  • Table 24: Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 25: Global Pre-Clinical Optical Imaging Reagents Market Size, By Type, 2012-2019 ($Million)
  • Table 26: Pre-Clinical Optical Imaging Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 27: Global Pre-Clinical Bioluminescent Imaging Reagents Market Size, By Type, 2012-2019 ($Million)
  • Table 28: Pre-Clinical Bioluminescent Imaging Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 29: Pre-Clinical Luciferins Market Size, By Region, 2012-2019 ($Million)
  • Table 30: Pre-Clinical Proluciferins Market Size, By Region, 2012-2019 ($Million)
  • Table 31: Pre-Clinical Coelenterazine Market Size, By Region, 2012-2019 ($Million)
  • Table 32: Other Pre-Clinical Bioluminescent Imaging Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 33: Global Pre-Clinical Fluorescent Imaging Reagents Market Size, By Type, 2012-2019 ($Million)
  • Table 34: Pre-Clinical Fluorescent Imaging Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 35: Pre-Clinical Green Fluorescent Proteins Market Size, By Region, 2012-2019 ($Million)
  • Table 36: Pre-Clinical Red Fluorescent Proteins Market Size, By Region, 2012-2019 ($Million)
  • Table 37: Pre-Clinical Infrared Dyes Market Size, By Region, 2012-2019 ($Million)
  • Table 38: Other Pre-Clinical Fluorescent Imaging Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 39: Global Pre-Clinical Nuclear Imaging Reagents Market Size, By Type, 2012-2019 ($Million)
  • Table 40: Pre-Clinical Nuclear Imaging Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 41: Global Pre-Clinical PET Tracers Market Size, By Type, 2012-2019 ($Million)
  • Table 42: Pre-Clinical PET Tracers Market Size, By Region, 2012-2019 ($Million)
  • Table 43: Fluorine-18-Based Pre-Clinical PET Tracers Market Size, By Region, 2012-2019 ($Million)
  • Table 44: Carbon-11-Based Pre-Clinical PET Tracers Market Size, By Region, 2012-2019 ($Million)
  • Table 45: Copper-64-Based Pre-Clinical PET Tracers Market Size, By Region, 2012-2019 ($Million)
  • Table 46: Other Pre-Clinical PET Tracers Market Size, By Region, 2012-2019 ($Million)
  • Table 47: Global Pre-Clinical SPECT Probes Market Size, By Type, 2012-2019 ($Million)
  • Table 48: Pre-Clinical SPECT Probes Market Size, By Region, 2012-2019 ($Million)
  • Table 49: Technetium-99m-Based Pre-Clinical SPECT Probes Market Size, By Region, 2012-2019 ($Million)
  • Table 50: Iodine-131-Based Pre-Clinical SPECT Probes Market Size, By Region, 2012-2019 ($Million)
  • Table 51: Gallium-67-Based Pre-Clinical SPECT Probes Market Size, By Region, 2012-2019 ($Million)
  • Table 52: Thallium-201-Based Pre-Clinical SPECT Probes Market Size, By Region, 2012-2019 ($Million)
  • Table 53: Other Pre-Clinical SPECT Probes Market Size, By Region, 2012-2019 ($Million)
  • Table 54: Global Pre-Clinical MRI Contrast Agents Market Size, By Type, 2012-2019 ($Million)
  • Table 55: Pre-Clinical MRI Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 56: Gadolinium-Based Pre-Clinical MRI Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 57: Iron-Based Pre-Clinical MRI Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 58: Manganese-Based Pre-Clinical MRI Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 59: Pre-Clinical Ultrasound Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 60: Global Pre-Clinical CT Contrast Agents Market Size, By Type, 2012-2019 ($Million)
  • Table 61: Pre-Clinical CT Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 62: Iodine-Based Pre-Clinical CT Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 63: Barium-Based Pre-Clinical CT Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 64: Gold Nanoparticles Pre-Clinical CT Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 65: Gastrografin-Based Pre-Clinical CT Contrast Agents Market Size, By Region, 2012-2019 ($Million)
  • Table 66: Global Systems and Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 67: North America: Pre-Clinical Imaging Market, By Product, 2012-2019 ($Million)
  • Table 68: North America: Systems Market, By Modality, 2012-2019 ($Million)
  • Table 69: U.S.: Systems Market, By Modality, 2012-2019 ($Million)
  • Table 70: North America: Reagents Market, By Type, 2012-2019 ($Million)
  • Table 71: Europe: Pre-Clinical Imaging Market, By Product, 2012-2019 ($Million)
  • Table 72: Europe: Systems Market, By Modality, 2012-2019 ($Million)
  • Table 73: Europe: Reagents Market, By Type, 2012-2019 ($Million)
  • Table 74: Asia-Pacific: Pre-Clinical Imaging Market, By Product, 2012-2019 ($Million)
  • Table 75: Asia-Pacific: Systems Market, By Modality, 2012-2019 ($Million)
  • Table 76: Asia-Pacific: Reagents Market, By Type, 2012-2019 ($Million)
  • Table 77: RoW: Pre-Clinical Imaging Market, By Product, 2012-2019 ($Million)
  • Table 78: RoW: Systems Market, By Modality, 2012-2019 ($Million)
  • Table 79: RoW: Reagents Market, By Reagents, 2012-2019 ($Million)
  • Table 80: Top 5 New Product Launches and Product Developments, 2012-2014
  • Table 81: Top 5 Agreements, Partnerships, and Collaborations, 2012-2014
  • Table 82: Top 5 Geographical Expansions, 2012-2014
  • Table 83: Mergers and Acquisitions, 2012-2014
  • Table 84: Top 5 Other Developments, 2012-2014

List of Figures

  • Figure 1: Pre-Clinical Imaging Market Research Methodology
  • Figure 2: Break Down of Supply Side Primary Interviews: By Company Type, Designation, and Region
  • Figure 3: Pre-Clinical Imaging Systems Market: Bottom Up Approach
  • Figure 4: Pre-Clinical Imaging Systems Market: Top-Down Approach
  • Figure 5: Pre-Clinical Imaging Reagents Market: Top-Down Approach
  • Figure 6: Pre-Clinical Imaging Market: Data Triangulation
  • Figure 7: Global Systems Market, 2014 ($Million)
  • Figure 8: Global Systems Market, 2014 vs. 2019
  • Figure 9: Global Reagents Market, 2014 vs. 2019
  • Figure 10: Global Pre-Clinical Imaging Market, By Region, 2014 ($Million)
  • Figure 11: Emerging Countries Offering High Growth Opportunities to Players in the Pre-Clinical Imaging Market
  • Figure 12: North America Commands the Largest Share of the Global Reagents Market
  • Figure 13: Optical, Nuclear, MRI, & Ultrasound Imaging Systems Command the Largest Share of the Global Systems Market
  • Figure 14: Over 80% of the Global Pre-Clinical Imaging Systems Market Will Be Dominated By Optical, Nuclear, & MRI Systems in 2019
  • Figure 15: Pre-Clinical Imaging Market Segmentation
  • Figure 16: Pre-Clinical Imaging Market Segmentation, By Modality
  • Figure 17: Pre-Clinical Imaging Reagents Market Segmentation, By Reagent
  • Figure 18: Pre-Clinical Imaging Market Drivers, Restraints, Opportunities, & Challenges
  • Figure 19: Advancements in Molecular Imaging Technologies Boosting the Adoption of These Systems in Pre-Clinical Research Studies
  • Figure 20: High Cost of Imaging Systems and Reduced Nih Funding Are Restricting the Growth of Pre-Clinical Imaging Market
  • Figure 21: Emerging Economies Offering High Growth Potential for Pre-Clinical Imaging Market
  • Figure 22: Technological Limitations of Individual Imaging Modalities is A Key Growth Challenge for Standalone Pre-Clinical Imaging Device Providers
  • Figure 23: Value Chain of Systems Market
  • Figure 24: Pre-Clinical Imaging Market Players Prefer Both Direct & Indirect Distribution Strategies
  • Figure 25: Porter's Five Forces Analysis, 2014
  • Figure 26: Pre-Clinical Imaging Systems Market, By Modality, 2014 vs. 2019 ($Million): Nuclear Imaging Systems Market to Grow at the Fastest Rate
  • Figure 27: The Bioluminescence/Fluorescence Imaging Systems Segment Holds A Major Share of the Pre-Clinical Optical Imaging Systems Market (2014)
  • Figure 28: The Asia-Pacific Pre-Clinical Optical Imaging Systems Market is Expected to Grow at A High Rate From 2014 to 2019
  • Figure 29: The Asia-Pacific Pre-Clinical Bioluminescence/Fluorescence Imaging Systems Market is Expected to Grow at A Double Digit Rate During the Forecast Period
  • Figure 30: The Standalone Fluorescence Imaging Systems Market is Expected to Witness Sluggish Growth in All Geographic Regions
  • Figure 31: Demand for Optical + X-Ray/Optical + CT Imaging Systems is Expected to Grow Rapidly in the Asia-Pacific Region
  • Figure 32: The Micro-PET Systems Segment Holds the Largest Share of the Pre-Clinical Nuclear Imaging Systems Market in 2014
  • Figure 33: North America Covers the Largest Share of the Pre-Clinical Nuclear Imaging Systems Market in 2014
  • Figure 34: PET/MRI Systems Market is Expected to Grow at A Double-Digit Rate During the Forecast Period
  • Figure 35: Asia-Pacific is Expected to Outpace the European Micro-PET Systems Market By 2019
  • Figure 36: North America Will Continue to Dominate the Micro-SPECT Systems Market in the Next Five Years
  • Figure 37: The Asia-Pacific Micro-MRI Systems Market is Expected to Equal the Market Size of the North American Market By 2019
  • Figure 38: North America Will Continue to Dominate the Global Micro-Ultrasound Systems Market By 2019
  • Figure 39: North America Holds the Largest Share of the Global Micro-CT Systems Market in 2014
  • Figure 40: North America is Expected to Be the Second-Fastest-Growing Market for Pre-Clinical Photoacoustic Imaging Systems After Asia-Pacific During The Forecast Period
  • Figure 41: Global Reagents Market, 2014 vs. 2019 ($Million): MRI Contrast Agents Market to Grow at the Fastest Rate
  • Figure 42: Bioluminescent Imaging Reagents Segment Will Continue to Dominate the Pre-Clinical Optical Imaging Reagents Market in the Forecast Period
  • Figure 43: Asia-Pacific Pre-Clinical Optical Imaging Reagents Market is Expected to Grow at the Highest CAGR in the Next Five Years
  • Figure 44: Luciferins to Command the Largest Share of Bioluminescent Imaging Reagents Market in 2014
  • Figure 45: Asia-Pacific Region is Estimated to Witness the Highest Growth Rate in the Bioluminescent Imaging Reagents Market
  • Figure 46: Infrared Dyes Account for the Largest Share of Pre-Clinical Fluorescent Imaging Reagents Market in 2014
  • Figure 47: Asia-Pacific and ROW Regions Will Drive the Growth of Pre-Clinical Fluorescent Imaging Reagents Market During the Forecast Period
  • Figure 48: PET Tracers Will Continue to Dominate the Pre-Clinical Nuclear Imaging Reagents Market in the Next Five Years
  • Figure 49: North America Accounts for the Largest Share of the Global Pre-Clinical Nuclear Imaging Reagents Market in 2014
  • Figure 50: Fluorine-18-Based PET Tracers Command the Lion's Share of Pre-Clinical PET Tracers Market in 2014
  • Figure 51: Technetium-99m-Based SPECT Probes Command the Lion's Share of Pre-Clinical SPECT Probes Market in 2014
  • Figure 52: Gadolinium-Based MRI Contrast Agents Command the Largest Share of Pre-Clinical MRI Contrast Agents Market in 2014
  • Figure 53: Asia-Pacifica MRI Contrast Agents Market is Estimated to Grow at the Highest Rate During the Forecast Period
  • Figure 54: North America Accounts for the Major Share of the Pre-Clinical Ultrasound Contrast Agents Market in 2014
  • Figure 55: Iodine-Based Contrast Agents Hold the Largest Share of Pre-Clinical CT Contrast Agents Market in 2014
  • Figure 56: Pre-Clinical Imaging Market , By Region, 2014 vs. 2019 ($Million): Asia-Pacific to Grow at the Highest Rate During the Forecast Period
  • Figure 57: North American Pre-Clinical Imaging Market Snapshot (2014-2019): Growth is Driven By High Adoption of Innovative Technologies
  • Figure 58: European Pre-Clinical Imaging Market Snapshot (2014-2019): Growth is Driven By Increased Government Funding for Developing European Research Sector
  • Figure 59: Asia-Pacific Pre-Clinical Imaging Market Snapshot (2014-2019): Growth is Driven By Rising Government Investment in Pharmaceutical R&D
  • Figure 60: Leading Pre-Clinical Imaging Market Players Adopted New Product Launches as the Key Growth Strategy Over the Last Three Years (2012-2014)
  • Figure 61: Global Pre-Clinical Imaging Market Share, By Key Player, 2013
  • Figure 62: Battle for Pre-Clinical Imaging Market Share: New Product Launches is the Key Strategy
  • Figure 63: Perkinelmer, Inc.: Company Snapshot
  • Figure 64: Bruker Corporation: Company Snapshot
  • Figure 65: Fujifilm Holdings Corporation.: Company Snapshot
Back to Top